share_log

Recursion Pharmaceuticals | 424B5: Prospectus

Recursion Pharmaceuticals | 424B5: Prospectus

Recursion Pharmaceuticals | 424B5：募資說明書
美股sec公告 ·  06/27 13:08
Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of 30,769,230 shares of its Class A common stock at a public offering price of $6.50 per share. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is detailed in the prospectus supplement dated June 26, 2024. The shares are listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The last reported sale price of Recursion's Class A Common Stock on Nasdaq was $8.76 per share as of June 26, 2024. The underwriters for the offering are Goldman Sachs & Co. LLC, J.P. Morgan, and Allen & Company LLC, who have the option to purchase an additional 4,615,384 shares. The offering is expected to close on or about June 28, 2024. The net proceeds from the offering, estimated at approximately $188.9 million before expenses, are intended for the advancement of Recursion's preclinical and clinical programs, platform technologies, and for general corporate purposes, including potential strategic investments and acquisitions.
Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of 30,769,230 shares of its Class A common stock at a public offering price of $6.50 per share. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is detailed in the prospectus supplement dated June 26, 2024. The shares are listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The last reported sale price of Recursion's Class A Common Stock on Nasdaq was $8.76 per share as of June 26, 2024. The underwriters for the offering are Goldman Sachs & Co. LLC, J.P. Morgan, and Allen & Company LLC, who have the option to purchase an additional 4,615,384 shares. The offering is expected to close on or about June 28, 2024. The net proceeds from the offering, estimated at approximately $188.9 million before expenses, are intended for the advancement of Recursion's preclinical and clinical programs, platform technologies, and for general corporate purposes, including potential strategic investments and acquisitions.
Recursion Pharmaceuticals, Inc.（Recursion）宣佈以每股6.50美元的公開發行價發行30,769,230股A類普通股，根據證券交易委員會（SEC）的424(b)(5)規定進行申報，詳見於2024年6月26日的招股書補充文件。股票在納斯達克全球精選市場上以“RXRX”爲代碼進行交易。截至2024年6月26日，Recursion的A類普通股在納斯達克的最後報價爲每股8.76美元。本次發行的承銷商爲高盛、摩根大通和艾倫公司有限責任公司，他們享有購買另外4,615,384股股票的選擇權。預計發行將於2024年6月28日左右結束。發行的淨收益約爲1.889億美元，用於推動Recursion的臨床前和臨床計劃、平台技術以及一般公司用途，包括潛在的戰略投資和收購。
Recursion Pharmaceuticals, Inc.（Recursion）宣佈以每股6.50美元的公開發行價發行30,769,230股A類普通股，根據證券交易委員會（SEC）的424(b)(5)規定進行申報，詳見於2024年6月26日的招股書補充文件。股票在納斯達克全球精選市場上以“RXRX”爲代碼進行交易。截至2024年6月26日，Recursion的A類普通股在納斯達克的最後報價爲每股8.76美元。本次發行的承銷商爲高盛、摩根大通和艾倫公司有限責任公司，他們享有購買另外4,615,384股股票的選擇權。預計發行將於2024年6月28日左右結束。發行的淨收益約爲1.889億美元，用於推動Recursion的臨床前和臨床計劃、平台技術以及一般公司用途，包括潛在的戰略投資和收購。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息